The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI).
The study has received a £1.5m fund from the National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme and will involve 25 hospitals in the UK and one in the Republic of Ireland, reported Pharmatimes.com.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
University of Edinburgh centre for genomic and experimental medicine professor Stuart Ralston was quoted by the BBC as saying: “This is potentially a game-changing trial since it is the first study that had been specifically designed to investigate whether any treatment can prevent fractures in osteogenesis imperfecta.
“If the results are positive, it could herald a new dawn in the treatment of this rare but devastating condition.”
OI is caused due to genetic mutations, which in turn leads to abnormalities in the collagen content of bone. It results in brittle bones, which can break easily even due to a mild trauma or sometimes for no reason, reported BBC.
The trial will assess the combination of two therapies in 390 people suffering with OI. About 50% of the patients will be administered with teriparatide followed by zoledronic acid, while the other half will be put through standatd care, reported news agencies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoth therapies are individually validated to treat this problem and this is the first time they will be tested in combination to treat OI.
